Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus
The use of GLP1-RAs decreased the risk of a composite outcome of renal dysfunction and mortality, improved metabolic control and showed safety of use in a large cohort of diabetic KTR, suggesting reno-protective effects in this high-risk population. Prospective data is further needed in KTR who are excluded from large RCTs.
Authors
- Yaron Rudman (ORCID: https://orcid.org/0000-0003-3220-6321)
- Idit Dotan (ORCID: https://orcid.org/0000-0003-0551-4759)
- Amit Akirov (ORCID: https://orcid.org/0000-0002-9376-344X)
- Talia Diker‐Cohen (ORCID: https://orcid.org/0000-0001-6211-2073)
- Bronya Calvarysky (ORCID: https://orcid.org/0009-0008-5124-0748)
- Adi Turjeman (ORCID: https://orcid.org/0000-0003-2200-9922)
- Tali Steinmetz (ORCID: https://orcid.org/0000-0002-5377-9156)
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Diabetes & Metabolism
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.diabet.2025.101624
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06